NCT00930865View on ClinicalTrials.gov

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Bumetanide

Tablets, Oral, 1 mg, Single Dose, 7 Days

DRUG

Dapagliflozin

Tablets, Oral, 10 mg. Single Dose, 7 Days

Trial Locations (1)

78744

Ppd Development, Lp, Austin

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY